← All trials

NCT07133178

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Feb 6, 2026
Primary completion
Dec 31, 2026
Completion date
Nov 30, 2027
First posted
Aug 20, 2025
Last posted
Sep 15, 2025
Enrollment
3000
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.